Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81,819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
Cui J, Zhu Z, Liu S, Li Q, Meng L, Cheng H, Zhong Z, Li W, You Y, Zhu X, Zou P. Cui J, et al. Among authors: li w, li q. Leuk Lymphoma. 2018 Sep;59(9):2264-2266. doi: 10.1080/10428194.2017.1421755. Epub 2018 Jan 16. Leuk Lymphoma. 2018. PMID: 29334838 No abstract available.
COVID-19 in persons with chronic myeloid leukaemia.
Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, You Y, Chen Z, Chen S, Wan C, Zhu X, Chang W, Sheng L, Cheng H, Zhang Y, Li Q, Qin J; Hubei Anti-Cancer Association; Meng L, Jiang Q. Li W, et al. Among authors: li q. Leukemia. 2020 Jul;34(7):1799-1804. doi: 10.1038/s41375-020-0853-6. Epub 2020 May 18. Leukemia. 2020. PMID: 32424293 Free PMC article.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: li z, li w. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: li z, li w. J Hematol Oncol. 2022 Oct 31;15(1):159. doi: 10.1186/s13045-022-01369-2. J Hematol Oncol. 2022. PMID: 36316695 Free PMC article. No abstract available.
81,819 results
You have reached the last available page of results. Please see the User Guide for more information.